Lee Ainslie’s Royalty Pharma RPRX Stock Holding History

Lee Ainslie’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-7,342	Closed	-$320K	–	819
2021 Q1	$320K	Buy	+7,342	New	+$348K	﹤0.01%	428

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCG

Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Lee Ainslie's RPRX Position: Q2 2021 in Review

Lee Ainslie sold out of Royalty Pharma (RPRX) in Q2 2021, closing a stake of 7,342 shares — an estimated $320K sold.

Lee Ainslie first reported a position in RPRX in Q1 2021 and held it in 1 quarter. The position peaked at $320K in Q1 2021. 236 funds tracked by Wall St. Rank hold RPRX as of Q2 2021.

Lee Ainslie reported no remaining Royalty Pharma position as of Q2 2021 after selling out during the quarter.
Lee Ainslie sold 7,342 Royalty Pharma shares in Q2 2021, an estimated $320K.
Lee Ainslie first reported a position in Royalty Pharma in Q1 2021 and held it in 1 quarter.
Lee Ainslie's Royalty Pharma position peaked at $320K in Q1 2021.
236 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2021.

Based on Maverick Capital's 13F filing for Q2 2021, filed 16 Aug 2021.